Latest

The A-TANGO consortium performs Phase 2 clinical studies of an innovative therapeutic strategy that targets inflammation and improves hepatocyte proliferation. This novel combinatorial therapy is called G-TAK. In addition, A-TANGO strives to…

MICROB-PREDICT aims to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis), when such decompensated cirrhosis will progress to…

Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) funded by the European Innovative Medicines Initiative 2 Joint Undertaking, brings together clinicians and scientists from prominent academic centres across Europe with companies from…

EASL is pleased to announce the release of the EASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma to coincide with the EASL Liver Cancer Summit 2023. Intrahepatic cholangiocarcinoma (iCCA) represents…

Join the global movement. Celebrate World Liver Day with us on 19 April 2023!  We are excited to announce World Liver Day, taking place TODAY, 19 April 2023. This global movement led by the European…

Dear colleagues and friends: We have to share the sad news that Peter Ferenci has passed away on 11 April 2023 just a few weeks before his 75th birthday. He recently celebrated…

The European Association for the Study of the Liver (EASL) and the Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) have issued a joint statement on metabolic dysfunction-associated fatty liver disease (MAFLD),…